PTC Therapeutics Phase III Duchenne Muscular Dystrophy (DMD) Clinical Trial | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

PTC Therapeutics Phase III Duchenne Muscular Dystrophy (DMD) Clinical Trial


 

PTC Therapeutics, Inc. is seeking patients with Nonsense Mutation Duchenne muscular dystrophy (DMD) to participate in a phase 3 research study to evaluate the safety and efficacy of ataluren.  Ataluren has been shown to enable the formation of full-length, functional dystrophin protein, thereby potentially stabilizing or slowing disease progression in patients with DMD.

 

Download the PTCT 041 Fact Sheet

 

For additional information, please contact: medinfo@ptcbio.com.

For additional information: https://clinicaltrials.gov/ct2/show/NCT03179631

https://www.duchennexchange.org/wp-content/uploads/2017/07/ptc.jpg